These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 38100555)

  • 1. Cancer drugs with high repositioning potential for Alzheimer's disease.
    Majeed J; Sabbagh MN; Kang MH; Lawrence JJ; Pruitt K; Bacus S; Reyna E; Brown M; Decourt B
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):311-332. PubMed ID: 38100555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
    Bullain S; Doody R
    J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer drugs repurposed for Alzheimer's disease: a systematic review.
    Ancidoni A; Bacigalupo I; Remoli G; Lacorte E; Piscopo P; Sarti G; Corbo M; Vanacore N; Canevelli M
    Alzheimers Res Ther; 2021 May; 13(1):96. PubMed ID: 33952306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug Repositioning for Alzheimer's Disease].
    Ihara M; Saito S
    Brain Nerve; 2019 Sep; 71(9):961-970. PubMed ID: 31506398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer's Disease: Current Perspectives and Challenging Prospects.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neuroscience; 2021 Aug; 469():191-196. PubMed ID: 34139302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
    Leßmann V; Kartalou GI; Endres T; Pawlitzki M; Gottmann K
    J Neural Transm (Vienna); 2023 Aug; 130(8):1003-1012. PubMed ID: 37014414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development.
    Cummings JL; Osse AML; Kinney JW; Cammann D; Chen J
    CNS Drugs; 2024 Aug; 38(8):613-624. PubMed ID: 38937382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer's Disease.
    Chyr J; Gong H; Zhou X
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development in Alzheimer's disease: the path to 2025.
    Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
    Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.